Setd1b: A Potential Drug Target for Various Diseases (G23067)

Target Name: SETD1B

NCBI ID: G23067

SETD1B

Setd1b: A Potential Drug Target for Various Diseases

Setd1b (Lysine N-methyltransferase 2G) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Setd1b is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been associated with the development and progression of various diseases.

The SETD1 gene family consists of four genes, including SETD1A, SETD1B, SETD3, and SETD4. Setd1b is the second gene in the family and is responsible for producing the protein SETD1b. SETD1b is a 21-kDa protein that has been shown to have various functions in different cellular processes, including cell signaling, DNA replication, and gene expression.

One of the most significant functions of SETD1b is its role in the regulation of gene expression. SETD1b has been shown to play a role in the regulation of gene expression by modifying the activity of microRNAs (miRNAs), which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

SETD1b has been shown to work by binding to specific target genes and modifying their miRNA expression levels. This process is known as SETD1b-mediated gene repression, and it is a critical mechanism by which SETD1b regulates cellular processes and ensures the stability of different cellular states.

In addition to its role in gene expression regulation, SETD1b has also been shown to play a role in the regulation of DNA replication.SETD1b has been shown to be involved in the regulation of DNA replication by working with the protein DNMTase, which is responsible for removing DNA methylation marks from the replicated DNA strand.

SETD1b has also been shown to be involved in the regulation of cell signaling pathways.SETD1b has been shown to play a role in the regulation of various signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

In addition to its role in cellular signaling pathways, SETD1b has also been shown to play a role in the development and progression of various diseases.SETD1b has been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SETD1b has also been shown to be a potential biomarker for several diseases.SETD1b has been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, Setd1b (Lysine N-methyltransferase 2G) is a gene that has been identified as a potential drug target or biomarker for various diseases. Its role in the regulation of gene expression, DNA replication, and cellular signaling pathways, as well as its association with the development and progression of various diseases make it an attractive target for further research. Further studies are needed to fully understand the role of Setd1b in disease and to develop effective treatments.

Protein Name: SET Domain Containing 1B, Histone Lysine Methyltransferase

Functions: Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism (PubMed:25561738, PubMed:17355966). Part of chromatin remodeling machinery, forms H3K4me1, H3K4me2 and H3K4me3 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:25561738, PubMed:17355966). Plays an essential role in regulating the transcriptional programming of multipotent hematopoietic progenitor cells and lymphoid lineage specification during hematopoiesis (By similarity)

The "SETD1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets